Capital Group Investment Management Pte. Ltd. Bei Gene, Ltd. Transaction History
Capital Group Investment Management Pte. Ltd.
- $475 Million
- Q3 2024
A detailed history of Capital Group Investment Management Pte. Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital Group Investment Management Pte. Ltd. holds 16,030 shares of BGNE stock, worth $2.91 Million. This represents 0.76% of its overall portfolio holdings.
Number of Shares
16,030
Previous 16,030
-0.0%
Holding current value
$2.91 Million
Previous $2.29 Million
57.32%
% of portfolio
0.76%
Previous 0.51%
Shares
5 transactions
Others Institutions Holding BGNE
# of Institutions
252Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.92 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.17 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$940 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$903 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$673 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $18.8B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...